tirzepatide diabetic retinopathy risk Diabetes Distilled: treatment associated with increased proliferative but possible reduced new retinopathy Comparative ocular outcomes of tirzepatide

469 In contrast, the liver and serum NAMPT of morbidly obese women with NAFLD are significantly higher than that of morbidly obese women with healthy livers

Tirzepatide, the active compound in Zepbound, works by activating GLP-1 and GIP receptors to reduce hunger and improve blood sugar controlbut this mechanism can trigger temporary side effects in some patients

Who it's for: Children and adolescents (and some adults) with sudden-onset behavioral, psychiatric, or neurological changes - particularly when standard workup is unrevealing

GLP-1R Race in 2025: 8 Essential Takeaways Drug Developers Need to Know Currently Playing Post:GLP-1R Race in 2025: 8 Essential Takeaways Drug Developers Need to Know In late 2025, a seemingly narrow advertising dispute told a much bigger story about the GLP-1 market

I loved going to that Montreal Comedy Festival

What is Tirzepatide?+ Tirzepatide (research code LY3298176) is a synthetic 39-amino-acid peptide engineered to act as a single-molecule dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor